Tryp Therapeutics Inc (TRYP) Corporate Media Kit

Investor Overview D Focused on developing psychedelic compounds for diseases with high unmet medical needs through accelerated regulatory pathways D Two psilocybin-based drug candidates in development: TRP-8802 (targeting chronic pain and eating disorder indications for Phase 2a studies) and TRP-8803 (proprietary formulation and method of deliv- ery for Phase 2b and subsequent studies) D Through PFN™ program, focused on developing psilocybin-based drug therapies that offer increased efficacy and reduced risk of abuse or